Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study

Dinesen, 2010, The pattern and outcome of acute severe colitis, J Crohns Colitis, 4, 431, 10.1016/j.crohns.2010.02.001 Turner, 2007, Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression, Clin Gastroenterol Hepatol, 5, 103, 10.1016/j.cgh.2006.09.033 Laharie, 2012, Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial, Lancet, 380, 1909, 10.1016/S0140-6736(12)61084-8 Lichtiger, 1994, Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N Engl J Med, 330, 1841, 10.1056/NEJM199406303302601 Järnerot, 2005, Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study, Gastroenterology, 128, 1805, 10.1053/j.gastro.2005.03.003 Gibson, 2015, An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis, Clin Gastroenterol Hepatol, 13, 330, 10.1016/j.cgh.2014.07.041 Govani, 2020, Use of accelerated induction strategy of infliximab for ulcerative colitis in hospitalized patients at a tertiary care center, Dig Dis Sci, 65, 1800, 10.1007/s10620-019-05957-0 Sandborn, 2017, Tofacitinib as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 376, 1723, 10.1056/NEJMoa1606910 Honap, 2020, Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience, J Crohns Colitis, 14, 1385, 10.1093/ecco-jcc/jjaa075 Kotwani, 2020, Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience, J Crohns Colitis, 14, 1026, 10.1093/ecco-jcc/jjaa018 Berinstein, 2019, Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis, Clin Gastroenterol Hepatol, 17, 988, 10.1016/j.cgh.2018.11.022 Hanauer, 2019, Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis, Clin Gastroenterol Hepatol, 17, 139, 10.1016/j.cgh.2018.07.009 Dowty, 2014, The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans, Drug Metab Dispos, 42, 759, 10.1124/dmd.113.054940 Brandse, 2015, Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis, Gastroenterology, 149, 350, 10.1053/j.gastro.2015.04.016 Battat, 2021, Baseline clearance of infliximab is associated with requirement for colectomy in patients with acute severe ulcerative colitis, Clin Gastroenterol Hepatol, 19, 511, 10.1016/j.cgh.2020.03.072 Travis, 1996, Predicting outcome in severe ulcerative colitis, Gut, 38, 905, 10.1136/gut.38.6.905 Seah, 2016, Review article: the practical management of acute severe ulcerative colitis, Aliment Pharmacol Ther, 43, 482, 10.1111/apt.13491 Sandborn, 2012, Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis, N Engl J Med, 367, 616, 10.1056/NEJMoa1112168 Waljee, 2013, Comparison of imputation methods for missing laboratory data in medicine, BMJ Open, 3, 10.1136/bmjopen-2013-002847 Lynch, 2013, Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit, Aliment Pharmacol Ther, 38, 935, 10.1111/apt.12473 Turkeltaub, 2016, Platelet-to-albumin ratio is a predictor of colectomy within 90 days in patients hospitalized for severe ulcerative colitis, Gastroenterology, 111 Higgins Waljee, 2017, Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study, BMJ, 357, j1415, 10.1136/bmj.j1415 Melmed, 2013, Quality improvement in inflammatory bowel disease, Gastroenterol Hepatol (N Y), 9, 286 Panés, 2021, Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: results from the OCTAVE clinical trials, J Crohns Colitis, 10.1093/ecco-jcc/jjab065